Sjögren research hub

A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease

This study is looking at a new medicine called CLN-978 for people with Sjögren's disease. It's an early-stage study to see how safe it is and how well it works. The medicine is given as an injection under the skin.